Patents Examined by Kara R McMillian
  • Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
    Patent number: 10307485
    Abstract: A pharmaceutical composition is provided which contains a water soluble acid salt of a sympathomimetic amine, e.g., pseudoephedrine, and an additive, e.g., a volatile amine or other odorant, that is co-distillable, e.g., by steam distillation, with the sympathomimetic amine and/or its derivatives, e.g., its free base.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: June 4, 2019
    Assignee: Wyeth LLC
    Inventors: David Hugh Giamalva, Gary Bruce Anderson
  • Selective inhibitor of phosphatidylinositol 3-kinase-gamma
    Patent number: 10301304
    Abstract: The present invention relates to a compound useful as a selective inhibitor of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: May 28, 2019
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Michael John Boyd, Alex Aronov, Hardwin O'Dowd, Jeremy Green
  • 2×2×2 week dosing regimen for treating acting keratosis with pharmaceutical compositions formulated with 3.75% imiquimod
    Patent number: 10238644
    Abstract: Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: March 26, 2019
    Assignee: Medicis Pharmaceutical Corporation
    Inventors: Michael T. Nordsiek, Sharon F. Levy, James Hurn-Joung Lee, James H. Kulp, Kodumudi S. Balaji, Tze-Chiang Meng, Jason J. Wu, Valyn S. Bahm, Robert Babilon
  • Arylamide compounds and compositions and uses thereof
    Patent number: 10166232
    Abstract: The present invention discloses ophthalmic and otic compositions of facially amphiphilic antimicrobial polymers and oligomers and their uses, including their use in methods for treating and preventing ophthalmic infections and otic infections in humans and animals.
    Type: Grant
    Filed: October 9, 2015
    Date of Patent: January 1, 2019
    Assignee: Innovation Pharmaceuticals Inc.
    Inventor: Richard W. Scott
  • Enhanced anti-influenza agents conjugated with anti-inflammatory activity
    Patent number: 10130714
    Abstract: Novel dual-targeted, bifunctional anti-influenza drugs formed by conjugation with anti-inflammatory agents are disclosed. Exemplary drugs according to the invention include caffeic acid (CA)-bearing zanamivir (ZA) conjugates ZA-7-CA (1), ZA-7-CA-amide (7) and ZA-7-Nap (43) for simultaneous inhibition of influenza virus neuraminidase and suppression of proinflammatory cytokines. Synthetic methods for preparation of these enhanced anti-influenza conjugate drugs are provided. The synthetic bifunctional ZA conjugates act synergistically towards protection of mice lethally infected by H1N1 or H5N1 influenza viruses. The efficacy of ZA-7-CA, ZA-7-CA-amide and ZA-7-Nap conjugates is much greater than the combination therapy of ZA with anti-inflammatory agents.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 20, 2018
    Assignee: ACADEMIA SINICA
    Inventors: Chi-Huey Wong, Jim-Min Fang, Kung-Cheng Liu, Jia-Tsrong Jan, Yih-Shyun E. Cheng, Ting-Jen R. Cheng
  • Use of L-carnitine, salts and derivatives thereof for reducing or preventing fatigue and improving cognitive function
    Patent number: 10130602
    Abstract: The invention relates to the use of L-carnitine, a salt of L-carnitine, a derivative of L-carnitine and/or salt of a derivative of L-carnitine, as well as respective methods and compositions, for reducing or preventing fatigue and/or for improving cognitive function in an animal. The animal is preferably a healthy individual and the use is preferably a non-therapeutic use.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: November 20, 2018
    Assignee: Lonza Ltd.
    Inventors: Adriana Williams, Frauke Warrikoff, Ulla Freitas, Richard Sasse, Kevin Owen
  • Use of equol for treating androgen mediated diseases
    Patent number: 10111855
    Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), or metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: October 30, 2018
    Assignees: Brigham Young University, Colorado State University Research Foundation
    Inventors: Edwin Douglas Lephart, Trent D. Lund, Robert J. Handa
  • Aerosol pirfenidone and pyridone analog compounds and uses thereof
    Patent number: 10105356
    Abstract: Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: October 23, 2018
    Assignee: Avalyn Pharma Inc.
    Inventor: Mark William Surber
  • Aerosol pirfenidone and pyridone analog compounds and uses thereof
    Patent number: 10092552
    Abstract: Disclosed herein are formulations of pirfenidone or pyridone analog compounds for aerosolization and use of such formulations for aerosol administration of pirfenidone or pyridone analog compounds for the prevention or treatment of various fibrotic and inflammatory diseases, including disease associated with the lung, heart, kidney, liver, eye and central nervous system. In some embodiments, pirfenidone or pyridone analog compound formulations and delivery options described herein allow for efficacious local delivery of pirfenidone or pyridone analog compound. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures, indications and manufacturing processes for production and use of the compositions described.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: October 9, 2018
    Assignee: AVALYN PHARMA INC.
    Inventor: Mark William Surber
  • Method of treating cancer using selective estrogen receptor modulators
    Patent number: 10071066
    Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: September 11, 2018
    Assignee: Duke University
    Inventors: Suzanne E. Wardell, Erik R. Nelson, Donald P. McDonnell
  • Substituted heteroaryl compounds and methods of use
    Patent number: 10059689
    Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.
    Type: Grant
    Filed: October 10, 2015
    Date of Patent: August 28, 2018
    Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Weilong Dai, Haiyang Hu, Tao Zhang, Wuhong Chen
  • Tetrahydrocyclopentapyrrole derivatives and a method for preparing the same
    Patent number: 10039747
    Abstract: The present invention provides tetrahydrocyclopentapyrrole derivatives that can be used for preventing or treating peptic ulcer, gastritis or reflux esophagitis, a method for preparing the same, and a pharmaceutical composition containing the same.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: August 7, 2018
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Kyung A Yu, Ji Sung Yoon, Deok Ki Eom, Yeon Im Lee, Mi Ryeong Han, Jun Hee Lee, Ha Nee Seo, Ji Duck Kim, Sang Ho Lee
  • Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
    Patent number: 10039722
    Abstract: Methods of treating or suppressing oxidative stress diseases and symptoms related to oxidative stress affecting normal electron flow in the cells or caused by reactive oxygen species with redox-active therapeutics. Use of redox-active therapeutics for the reduction, suppression or treatment of oxidative stress induced by chemical agents such as contrast agents and other nephrotoxic agents, by radiation exposure, and by disruptions in the transport of oxygen to tissues, is disclosed.
    Type: Grant
    Filed: October 13, 2009
    Date of Patent: August 7, 2018
    Assignee: BIOELECTRON TECHNOLOGY CORPORATION
    Inventor: Guy M. Miller
  • Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
    Patent number: 10039764
    Abstract: Disclosed are methods for treating cancer and precancerous conditions with PDE10A specific inhibitors and diagnosis of neoplastic diseases based on elevated levels of PDE10A.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: August 7, 2018
    Assignee: University of South Alabama
    Inventor: Gary A. Piazza
  • Antifungal composition
    Patent number: 9968591
    Abstract: Disclosed is a pharmaceutical composition for antifungal use, comprising: 1) one or more compounds selected from compounds represented by the general formula (1) below and physiologically acceptable salts thereof; 2) one or more compounds selected from polypropylene glycol, diesters of dibasic acids, triacetin, 2-ethyl-1,3-hexanediol, lauromacrogol, and polyoxyethylene-polyoxypropylene glycol; and 3) one or more compounds selected from glucono-?-lactone, propylene glycol, glycerin, and lactic acid. General formula (1) (In the formula, X represents a halogen or hydrogen). wherein X represents a halogen or hydrogen.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: May 15, 2018
    Assignees: Pola Pharma Inc., Nihon Nohyaku CO., LTD.
    Inventors: Takaaki Masuda, Naoto Nishida, Naoko Kobayashi, Hideaki Sasagawa
  • Use of small molecule inhibitors targeting EYA tyrosine phosphatase
    Patent number: 9962362
    Abstract: Inhibitors of EYA tyrosine phosphatase are provided herein, as well as pharmaceutical compositions and methods relating thereto.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: May 8, 2018
    Assignee: Children's Hospital Medical Center
    Inventor: Rashmi Hegde
  • Compositions and methods for treating proliferation disorders
    Patent number: 9949981
    Abstract: The present invention relates to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-(3-morpholinophenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine or N-(1-(3-(3-(4-(1-aminocyclobutyl)phenyl)-2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-5-yl)phenyl)piperidin-4-yl)-N-methylacetamide. The methods of the present invention can also relate to methods of treating cell proliferative disorders, such as cancer or Proteus syndrome, by utilizing the above compounds in combination with ((R)-6-(2-fluorophenyl)-N-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine).
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: April 24, 2018
    Assignee: ArQule, Inc.
    Inventors: Daniel T. Dransfield, Sudharshan Eathiraj, Jean-Marc Lapierre, Brian Schwartz, Yi Yu
  • Method for treating cerebral amyloid angiopathy using pharmacological chaperones to increase the activity of gangliosidases
    Patent number: 9931353
    Abstract: The present invention relates to a method for treating an individual having Cerebral Amyloid Angiopathy by using pharmacological chaperones to increase the activity of gangliosidase and/or sialidase enzymes involved in ganglioside catabolism.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: April 3, 2018
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Brandon Alan Wustman, Kenneth Valenzano, Robert Boyd
  • Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
    Patent number: 9901578
    Abstract: The present invention relates to compositions comprising a combination of 10-propargyl-10-deazaaminopterin and an EGFR Kinase inhibitor, including erlotinib, for treatment of non-small cell lung cancer, and methods of treatment for non-small cell lung cancer in a patient in need thereof comprising administering for combination of 10-propargyl-10-deazaaminopterin and an EGFR Kinase inhibitor, including erlotinib, for treatment of non-small cell lung cancer.
    Type: Grant
    Filed: July 17, 2013
    Date of Patent: February 27, 2018
    Assignee: ALLOS THERAPEUTICS, INC.
    Inventor: Gijsbertus J. Pronk
  • Use of equol for treating androgen mediated diseases
    Patent number: 9889116
    Abstract: Equol (7-hydroxy-3(4?hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5?-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: February 13, 2018
    Assignees: BRINGHAM YOUNG UNIVERSITY, COLORADO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Edwin Douglas Lephart, Trent D. Lund, Robert J. Handa